Frequency Therapeutics, Inc. (FREQ)
Stock Price:
$22.32 USD
0.35 (1.59%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
750.98M |
| Revenue (ttm) |
44.73M |
| Net Income (ttm) |
-17.01M |
| Shares Out |
33.65M |
| EPS (ttm) |
-10.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$22.32 |
| Previous Close |
$21.97 |
| Change ($) |
0.35 |
| Change (%) |
1.59% |
| Day's Open |
21.64 |
| Day's Range |
21.13 - 22.53 |
| Day's Volume |
145,524 |
| 52-Week Range |
13.60 - 28.78 |
More Stats
| Market Cap |
750.98M |
| Enterprise Value |
556.13M |
| Earnings Date (est) |
Nov 23, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.65M |
| Float |
28.77M |
| EPS (basic) |
3.80 |
| EPS (diluted) |
-10.29 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.21M |
| Short Ratio |
18.94 |
| Short % of Float |
14.62% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
16.79 |
| PB Ratio |
4.56 |
| Revenue |
44.73M |
| Operating Income |
-19.60M |
| Net Income |
-17.01M |
| Free Cash Flow |
n/a |
| Net Cash |
194.85M |
| Net Cash / Share |
5.79 |
| Gross Margin |
28.94% |
| Operating Margin |
-43.80% |
| Profit Margin |
-40.40% |
| FCF Margin |
n/a |
| ROA |
-10.22% |
| ROE |
-17.75% |
| ROIC |
55.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$32.33*
(44.85% upside)
Low
27.0
Current: $22.32
High
36.0
Target: 32.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 28.95 | - | - |
| Gross Profit | 28.95 | - | - |
| Operating Income | -20.68 | -18.94 | -16.31 |
| Net Income | -18.75 | -19.17 | -20.24 |
| Shares Outstanding | 8.65 | 1.53 | 0.70 |
| Earnings Per Share | -2.29 | -12.53 | -28.79 |
| Operating Cash Flow | 34.22 | -17.02 | -14.61 |
| Capital Expenditures | -1.06 | -0.44 | -1.86 |
| Free Cash Flow | 33.15 | -17.46 | -16.48 |
| Cash & Equivalents | 217 | 42.19 | 17.94 |
| Net Cash / Debt | 217 | 42.19 | 17.94 |
| Assets | 223 | 44.55 | 19.79 |
| Liabilities | 55.86 | 4.12 | 2.74 |
| Book Value | 167 | -52.06 | -29.64 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Frequency Therapeutics, Inc. |
| Country |
United States |
| Employees |
43 |
| CEO |
David L. Lucchino |
Stock Information
| Ticker Symbol |
FREQ |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FREQ |
| IPO Date |
October 3, 2019 |
Description
Frequency Therapeutics, a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.